Hutchmed Shares in Focus as Key Cancer Trial Data Presented
Published on 09/11/2025 at 09:00 | Redaktion boerse-global.deInvestor attention turns to Hutchmed (NASDAQ: HCM) this week as the biopharmaceutical company unveils significant clinical findings at the annual Chinese Society of Clinical Oncology (CSCO) congress in Jinan. The event serves as a major international platform for presenting advancements in oncology.
The market is closely monitoring two primary data presentations scheduled for Thursday. The first involves initial results from a Phase II trial. This study is evaluating Fruquintinib in combination with Camrelizumab, Liposomal Paclitaxel, and Nedaplatin as a potential first-line treatment for patients diagnosed with advanced esophageal squamous cell carcinoma.
Concurrently, the company will disclose updated results from a separate prospective, randomized study. This research assesses Surufatinib plus transarterial embolization versus Surufatinib as a standalone monotherapy for individuals with neuroendocrine tumors that have metastasized to... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
